Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MesenCure for COVID-19 ARDS
NCT05497401Phase 3Not yet recruiting
- Sponsor
- Bonus BioGroup
- Start
- Apr 2026
- Primary completion
- Jun 2028
- Modality
- Mesenchymal Stem Cells
01
Overview
A Phase 3 trial of MesenCure in acute respiratory distress syndrome (ARDS), coronavirus disease 2019 (COVID-19), sponsored by Bonus BioGroup. Planned start Apr 2026; status: not yet recruiting.
02
Drugs
MesenCure
03
Conditions
acute respiratory distress syndrome (ARDS)coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT05497401.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05497401.